baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Spero Therapeutics/ US84833T1034 /

14/06/2024 21:57:26	Chg. -0.01	Volume	Bid-	Ask-	High	Low
1.36USD	-0.37%	2,252 Turnover: 3,035.17	-Bid Size: -	-Ask Size: -	1.36	1.32

GlobeNewswire 03/06 Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 31/05 Verve Therapeutics Announces Leadership Update

GlobeNewswire 16/05 Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference

GlobeNewswire 15/05 Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update

GlobeNewswire 08/05 Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wed...

GlobeNewswire 01/05 Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 13/03 Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Busi...

GlobeNewswire 06/03 Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial...

GlobeNewswire 28/02 Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infect...

GlobeNewswire 26/02 Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference

GlobeNewswire 31/01 Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 05/01 Spero Therapeutics Provides Corporate Update and 2024 Outlook

GlobeNewswire 02/01 Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipe...

GlobeNewswire 21/11/2023 SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possib...

GlobeNewswire 13/11/2023 Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update

GlobeNewswire 06/11/2023 Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Mon...

GlobeNewswire 01/11/2023 Spero Therapeutics to Present at Upcoming November Investor Conferences

GlobeNewswire 01/11/2023 Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer

GlobeNewswire 31/10/2023 Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 29/09/2023 Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 20/09/2023 Spero Therapeutics to Present at Cantor’s Global Healthcare 2023 Investor Conference

GlobeNewswire 12/09/2023 Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of ...

GlobeNewswire 06/09/2023 Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire 05/09/2023 Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Sco...

GlobeNewswire 31/08/2023 Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Spero Therapeutics/ US84833T1034 /

If you wish to receive reply to your feedback, please provide your email address.